IRVINE, Calif., Aug. 30, 2005 (PRIMEZONE) -- The informational report "Innovations in Biotechnology" has been made available free of charge at www.SmallCapSentinel.com and will address stents and stent-related companies including MIV Therapeutics, Inc. (OTCBB:MIVT), Angiotech Pharmaceuticals Inc. (Nasdaq:ANPI), Conor Medsystems Inc. (Nasdaq:CONR), and Guidant Corp. (NYSE:GDT). The report will place specific emphasis on drug eluting stents, their design, application, and imperative need.
"The drug-eluting stent is a critical tool in the cardiologist's arsenal," stated SmallCap Sentinel analyst D.R. Clark. "And innovation within this niche should be heavily followed -- not just for its impact on the companies that bring them to market, but also for its potential to affect our collective health and longevity."
MIV Therapeutics shares have risen in excess of 135% from July 26 to yesterday's close, driven in part by a series announcements by and awards for the company. MIV Therapeutics, Inc. is a developer of next-generation biocompatible stent coatings and drug delivery technologies for cardiovascular stents for a broad range of implantable medical devices. The company also recently announced a $4.14 million equity financing that will accelerate research efforts.
Interested parties may view additional information about MIVT via this direct link: http://www.trilogy-capital.com/tcp/mivt/factsheet.html
Statements made herein contain forward-looking statements and are subject to significant risks and uncertainties that will affect results. SmallCap Sentinel and StockUpTicks.com are properties of Market Pathways Financial Relations Inc. (MP). MP provides no assurance as to the subject company's plans or ability to effect any proposed actions and cannot project capabilities, intent, resources, or experience.
All information contained herein is based upon sources believed to be reliable but no representation is made as to its accuracy or completeness. This report is neither a solicitation to buy nor an offer to sell securities but is rather a paid advertisement provided for information purposes only and should not be used as the basis for any investment decision. MP is not an investment advisor and this report is not investment advice. MP has been paid fifteen hundred dollars by MIV Therapeutics Corp. for preparation and distribution of this report and other advertising services. This constitutes a conflict of interest as to MP's ability to remain objective in its communication regarding the subject companies.